• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book Apps
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Opioids Not Superior to Other Medicines for Some Chronic Pain

Opioids Not Superior to Other Medicines for Some Chronic Pain

October 1, 2018
Rehan Aziz, MD
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Rehan Aziz, MD Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Krebs EE et al, JAMA 2018;319(9):872–882

Rising rates of opioid overdose deaths have sounded alarm bells over opioid prescribing practices for chronic pain. Unfortunately, and despite the absence of quality data on their risks vs benefits, long-term opioid management has remained a common approach to managing chronic musculoskeletal pain. CATR covered this topic in the 2018 May/June issue (See: “Treating Chronic Pain When There’s Addiction: A Primer”).

This study examined long-term outcomes in chronic pain with opioid vs non-opioid treatment. Researchers conducted a 12-month randomized trial evaluating patients who—despite analgesic use—had moderate to severe chronic back pain or hip/knee osteoarthritic pain. Patients were recruited from Veterans Affairs primary care clinics in Minneapolis, Minnesota between 2013 and 2015.

The study compared opioid and non-opioid therapy. Patients in each group were prescribed multiple medications over 3 steps. In total, 240 patients were randomized, with a mean age of 58.3 years; females made up 13% of the group.

In the opioid group, the first phase was immediate release morphine, oxycodone, or hydrocodone/acetaminophen. Second- and third-step options included sustained action morphine and transdermal fentanyl.

For the non-opioid group, the first stage was acetaminophen or an NSAID. Second- and third-phase choices comprised adjuvants, such as gabapentin or nortriptyline; topical analgesics; and drugs such as duloxetine and tramadol.

Outcomes measured included the impact of pain on daily functioning, rated on the Brief Pain Inventory [BPI] interference scale; pain intensity on the BPI severity scale; and adverse medication–related symptoms. The BPI interference scale records the influence of pain on activities like sleep, walking, relationships, work, and life enjoyment. For both BPI scales, the range is 0–10, with higher scores indicating worsened functioning or higher pain intensity.

Over 12 months, the groups did not significantly differ on pain-related function. The mean BPI interference was 3.4 for the opioid group and 3.3 for the non-opioid group. Unexpectedly, the non-opioid group reported significantly less pain intensity at 12 months, with a BPI severity of 4.0 for the opioid group and 3.5 for the non-opioid group. Adverse medication–related symptoms were significantly more common in the opioid group.

CATR’s Take
The noteworthy result here is that chronic pain patients on opioids may not be any better off than those taking alternative agents. While psychiatrists are not the primary treaters of musculoskeletal pain, the current opioid crisis has had wide-ranging impact, and there are calls for a multipronged approach. As such, and since many patients develop opioid dependence after long-term opioid treatment for chronic pain, we should be ready to share these results with our patients and medical colleagues.
Addiction Treatment
KEYWORDS addiction free_articles research-update substance_abuse
    Aziz
    Rehan Aziz, MD

    Breaking the Silence: Addressing the Hidden Crisis of Elder Abuse

    More from this author
    www.thecarlatreport.com
    Issue Date: October 1, 2018
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Addiction in Older Adults, CATR, October 2018
    Alcohol Use Disorder Meds in Older Adults
    Substance Use Disorder in Older Adults
    Low-Risk Drinking Limits: What Should We Tell Older Adult Patients?
    Opioids Not Superior to Other Medicines for Some Chronic Pain
    Effects of Cannabis Use on Smoking Cessation
    Note From the Editor-in-Chief
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2637648401.jpg
      General Psychiatry

      Psychopharm Secrets: Coming Off Meds

      There’s a hidden placebo response to watch for when patients stop meds on their own.
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.